| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2019 ( Subtotal = $1,996,782 ) |
| | 2019 | 2019 | INTABIO, INC. | 39655 EUREKA DR | NEWARK | CA | 94560-4806 | ALAMEDA | USA | R44TR002570 | Commercial Development of a Novel Microfluidic Platform for Real-Time Biopharmaceutical Analysis | 002 | 2 | NIH | 2/28/2019 | $1,996,782 |
| | 2019 | 2018 | INTABIO, INC. | 39655 EUREKA DR | NEWARK | CA | 94560-4806 | ALAMEDA | USA | R44TR002570 | Commercial Development of a Novel Microfluidic Platform for Real-Time Biopharmaceutical Analysis | 000 | 1 | NIH | 2/11/2019 | $0 |
| | 2019 | 2018 | INTABIO, INC. | 39655 EUREKA DR | NEWARK | CA | 94560-4806 | ALAMEDA | USA | R44TR002570 | Commercial Development of a Novel Microfluidic Platform for Real-Time Biopharmaceutical Analysis | 001 | 1 | NIH | 2/27/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $324,544 ) |
| | 2018 | 2018 | INTABIO, INC. | 39655 EUREKA DR | NEWARK | CA | 94560-4806 | ALAMEDA | USA | R44TR002570 | Commercial Development of a Novel Microfluidic Platform for Real-Time Biopharmaceutical Analysis | 000 | 1 | NIH | 8/10/2018 | $324,544 |
|
|
